Communiqués ARYA SCIE

Actions

ARYD

KYG316591083

Marché Fermé - Nasdaq 22:00:00 18/08/2026			Varia. 5j.	Varia. 1 janv.
0,6460 ^USD	-0,84%		-12,46%	-90,27%

13/09/24	ARYA Sciences Acquisition Corp IV publie ses résultats pour le deuxième trimestre et le semestre clos le 30 juin 2024	CI
31/07/24	Adagio Medical, Inc. a finalisé l'acquisition d'ARYA Sciences Acquisition Corp IV (NasdaqCM:ARYD) auprès d'un groupe d'actionnaires dans le cadre d'une opération de fusion inversée.	CI

Communiqués

31/07/24	Adagio Medical Announces the Closing of the Business Combination with ARYA IV, Creating a Publicly Traded Company Focused on the Innovative Technologies for Treatment of Cardiac Arrhythmias	BU
11/06/24	ARYA Sciences Acquisition IV : ADAGIO MEDICAL Investor Presentation \| June 2024 1 Form 8 K	PU
02/05/24	ARYA Sciences Acquisition IV : G220229/S002/A001 - Form 8-K	PU
29/03/24	ARYA Sciences Acquisition IV : Failure to Satisfy Listing Rule - Form 8-K	PU
14/02/24	Adagio Medical To List on Nasdaq Through Business Combination with ARYA Sciences Acquisition Corp IV, Enabling Further Commercial and Clinical Development of Innovative Cardiac Ablation Technologies	PR
03/10/23	ARYA Sciences Acquisition IV : New Financial Obligation - Form 8-K	PU
05/09/23	ARYA Sciences Acquisition IV : New Financial Obligation - Form 8-K	PU
02/08/23	ARYA Sciences Acquisition IV : New Financial Obligation - Form 8-K	PU
03/07/23	ARYA Sciences Acquisition Corp V will redeem its Class A Ordinary Shares and will not consummate an initial business combination	GL
06/04/23	ARYA SCIENCES ACQUISITION CORP IV Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	AQ
05/04/23	ARYA Sciences Acquisition IV : Non-Reliance on Previously Issued Financial Report - Form 8-K	PU
05/04/23	ARYA SCIENCES ACQUISITION CORP IV : Non-Reliance on Previous Financials, Audits or Interim Review (form 8-K)	AQ
01/03/23	ARYA SCIENCES ACQUISITION CORP IV : Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)	AQ
27/02/23	ARYA SCIENCES ACQUISITION CORP IV : Other Events (form 8-K)	AQ
07/11/22	ARYA SCIENCES ACQUISITION CORP IV Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ
07/11/22	ARYA SCIENCES ACQUISITION CORP IV : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities (form 8-K)	AQ
08/08/22	ARYA SCIENCES ACQUISITION CORP IV Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ
24/02/22	ARYA SCIENCES ACQUISITION IV : AND AMICUS THERAPEUTICS, INC. MUTUALLY AGREE TO TERMINATE BUSINESS COMBINATION AGREEMENT WITH RESPECT TO THE ACQUISITION OF AMICUS’ GENE THERAPY BUSINESS DUE TO MARKET CONDITIONS - Form 8-K	PU
13/01/22	ARYA Sciences Acquisition IV : As discussed in Note 2 to the financial statement, the March 2, 2021 financial statement has been restated to correct a certain misstatement - Form 8-K/A	PU
29/09/21	ARYA Sciences Acquisition IV : Business Combination of Amicus Gene Therapy Business with ARYA IV to Result in the Launch of Caritas Therapeutics, a New Independent, Publicly Traded Company with Expected ~$400M in Initial Funding (Form 8-K)	PU